CTIS2023-505783-11-00进行中（未招募）1 期
AC-01
Alk-Abello A/S0 个研究点目标入组 12 人开始时间: 2023年8月21日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Safety and Tolerability of AC01 in patients with heart failureMedDRA version: 20.0Level: LLTClassification code: 10078289Term: Heart failure with reduced ejection fraction Class: 10007541Heart FailureCTIS2022-500347-20-00Anacardio AB116
进行中（未招募）
1 期
A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men with Biochemical Recurrence after Definitive Local Therapy for Prostate CancerProstate CancerCTIS2023-504066-39-00Vaccitech PLC117
招募中
1 期
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic MalignanciesCTIS2022-501797-19-00AvenCell Europe GmbH60
进行中（未招募）
1 期
A Phase 1 Study of BMS-986406 as Monotherapy and in Combination in Advanced TumorsAdvanced Malignant TumorsMedDRA version: 21.0Level: LLTClassification code: 10048683Term: Advanced cancer Class: 10029104CTIS2023-508280-69-00Bristol Myers Squibb International Corporation112
进行中（未招募）
1 期
A trial in healthy volunteers to study safety, tolerability, CS014-levels and effects in the body, after single and repeated doses of CS014, for the first time in humans.Cardiovascular diseaseCTIS2024-510878-24-00Cereno Scientific AB48